{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:12:58Z","timestamp":1790388778122,"version":"4.1.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1097\/01.inf.0000258697.05341.2c","type":"journal-article","created":{"date-parts":[[2007,3,21]],"date-time":"2007-03-21T03:46:47Z","timestamp":1174448807000},"page":"345-350","source":"Crossref","is-referenced-by-count":41,"title":["New Zealand Epidemic Strain Meningococcal B Outer Membrane Vesicle Vaccine in Children Aged 16\u201324 Months"],"prefix":"10.1097","volume":"26","author":[{"given":"Sharon","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Lennon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Crengle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Tilman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingeborg","family":"Aaberge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"O'Hallahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Oster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Mulholland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-15-20210202","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1016\/j.vaccine.2005.01.050","article-title":"New Zealand's epidemic of meningococcal disease described using molecular analysis: implications for vaccine delivery.","volume":"23","author":"Dyet","year":"2005","journal-title":"Vaccine"},{"key":"R2-15-20210202","first-page":"125","article-title":"Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway.","volume":"14","author":"Bjune","year":"1991","journal-title":"NIPH Ann"},{"key":"R3-15-20210202","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1017\/S0950268800047713","article-title":"Serotype-specific outbreak of group B meningococcal disease in Iquique, Chile.","volume":"105","author":"Cruz","year":"1990","journal-title":"Epidemiol Infect"},{"key":"R4-15-20210202","first-page":"195","article-title":"Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba.","volume":"14","author":"Sierra","year":"1991","journal-title":"NIPH Ann"},{"key":"R5-15-20210202","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1128\/JCM.30.7.1734-1738.1992","article-title":"Ongoing group B Neisseria meningitidis epidemic in Sao Paulo, Brazil, due to increased prevalence of a single clone of the ET-5 complex.","volume":"30","author":"Saachi","year":"1992","journal-title":"J Clin Microbiol"},{"key":"R7-15-20210202","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","article-title":"Effect of an outer membrane vesicle vaccine against group B meningococcal disease in Norway.","volume":"338","author":"Bjune","year":"1991","journal-title":"Lancet"},{"key":"R8-15-20210202","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1128\/IAI.63.12.4642-4652.1995","article-title":"Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine.","volume":"63","author":"Rosenqvist","year":"1995","journal-title":"Infect Immun"},{"key":"R9-15-20210202","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0264-410X(02)00591-1","article-title":"Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease.","volume":"21","author":"Holst","year":"2003","journal-title":"Vaccine"},{"key":"R10-15-20210202","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0264-410X(94)00037-N","article-title":"Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1. 3) outer membrane protein vaccine in Iquique, Chile.","volume":"13","author":"Boslego","year":"1995","journal-title":"Vaccine"},{"key":"R11-15-20210202","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1128\/IAI.62.10.4419-4424.1994","article-title":"Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy.","volume":"62","author":"Milagres","year":"1994","journal-title":"Infect Immun"},{"key":"R12-15-20210202","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/0140-6736(92)93086-3","article-title":"Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil.","volume":"340","author":"de Moraes","year":"1992","journal-title":"Lancet"},{"key":"R13-15-20210202","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/ije\/24.5.1050","article-title":"Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study.","volume":"24","author":"Noronha","year":"1995","journal-title":"Int J Epidemiol"},{"key":"R14-15-20210202","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jama.281.16.1520","article-title":"Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomised controlled trial in Chile.","volume":"281","author":"Tappero","year":"1999","journal-title":"JAMA"},{"key":"R15-15-20210202","article-title":"Immunisation Handbook 2002.","year":"2002"},{"key":"R16-15-20210202","first-page":"67","article-title":"Production, characterization and control of MenB-Vaccine \u226aFolkehelsa\u226b: an outer membrane vesicle vaccine against group B meningococcal disease.","volume":"14","author":"Fredriksen","year":"1991","journal-title":"NIPH Ann"},{"key":"R17-15-20210202","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.vaccine.2005.09.043","article-title":"Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control.","volume":"24","author":"Thornton","year":"2006","journal-title":"Vaccine"},{"key":"R18-15-20210202","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.vaccine.2005.01.070","article-title":"Validation of the serum bactericidal assay for measurement of functional antibodies against group B meningococci associated with vaccine trials.","volume":"23","author":"Martin","year":"2005","journal-title":"Vaccine"},{"key":"R20-15-20210202","first-page":"125","article-title":"Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway.","volume":"14","author":"Bjune","year":"1991","journal-title":"NIPH Ann"},{"key":"R21-15-20210202","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1016\/S0264-410X(99)00036-5","article-title":"Neisseria meningitidis serogroup B outer membrane vesicle vaccine in adults with occupational risk for meningococcal disease.","volume":"17","author":"Fischer","year":"1999","journal-title":"Vaccine"},{"key":"R22-15-20210202","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1086\/514232","article-title":"Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland.","volume":"177","author":"Perkins","year":"1998","journal-title":"J Infect Dis"},{"key":"R24-15-20210202","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.vaccine.2005.01.048","article-title":"Evaluating the post-licensure effectiveness of a group B meningococcal vaccine in New Zealand: a multi-faceted strategy.","volume":"23","author":"Ameratunga","year":"2005","journal-title":"Vaccine"},{"key":"R25-15-20210202","first-page":"117","article-title":"The New Zealand meningococcal vaccine strategy: a tailor-made vaccine to combat a devastating epidemic.","author":"Sexton","year":"2004","journal-title":"N Z Med J"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.inf.0000258697.05341.2c","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:37:10Z","timestamp":1786034230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006454-200704000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/01.inf.0000258697.05341.2c","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}